Regeneron: Position for a 2026 Re-acceleration Backed by Pipeline and Cash Flow
Regeneron looks attractively valued for a 2026 re-acceleration. After a mixed quarter where Eylea faced pressure but company-level revenues and cash flow held up, the stock trades at ~17-18x forward earnings with strong free cash flow. Upcoming pipeline readouts, label expansions, and a material manufacturing buildout create a plausible path to dou…